. 2021 Mar 7;8(3):2058–2069. doi: 10.1002/ehf2.13285

Table 2.

Predictors of the achievement of LV reverse remodelling

	Reverse remodelling within 6 months ^a			Reverse remodelling within 12 months ^b
	Adjusted HR	95% CI	P‐value	Adjusted HR	95% CI	P‐value
SBP >110 mmHg	1.821	1.228–2.700	0.003	‐	‐	‐
SBP >120 mmHg	‐	‐	‐	1.355	1.010–1.818	0.043
Non‐ischaemic aetiology	‐	‐	‐	1.661	1.172–2.353	0.004
LV‐EF <25%	1.872	1.313–2.669	0.001	‐	‐	‐
LV‐EF <30%	‐	‐	‐	1.536	1.135–2.080	0.005
PASP <40 mmHg	1.536	1.048–2.253	0.028	‐	‐	‐

Univariable factors with P‐values <0.200 were entered into the multivariable Cox proportional hazard regression analysis, using the stepwise backward elimination method.

^{^a}

LV reverse remodelling within 6 months of sacubitril/valsartan treatment initiation was determined in 289 patients for whom follow‐up echocardiograms within 6 months were available. Multivariable Cox regression analysis was performed with these 289 patients.

^{^b}

LV reverse remodelling within 12 months of sacubitril/valsartan treatment initiation was determined in 371 patients for whom follow‐up echocardiograms within 6 months were available. Multivariable Cox regression analysis was performed with these 371 patients.

CI, confidence interval; LV‐EF, left ventricular ejection fraction; HR, hazard ratio; PASP, pulmonary artery systolic pressure; SBP, systolic blood pressure.